Table 1.
Entire cohort N (%) | Modeling set N (%) | Test set N (%) | P-value | |
---|---|---|---|---|
No. of patients | 115 | 50 | 65 | |
Age | 61.0 ± 12.0 | 62.9 ± 13.3 | 59.5 ± 10.7 | 0.1545 |
Sex | 0.0006 | |||
Female | 63 (54.8) | 18 (36.0) | 45 (69.2) | |
male | 52 (45.2) | 32 (64.0) | 20 (30.7) | |
Race | 0.8530 | |||
White | 54 (47.0) | 24 (48.0) | 30 (46.2) | |
Other | 61 (53.0) | 26 (52.0) | 35 (53.8) | |
Smoking | 1 | |||
Ever | 29 (90.6) | 16 (94.1) | 13 (86.7) | |
Never | 3 (9.4) | 1 (5.9) | 2 (13.3) | |
Comorbidity score | 0.8263 | |||
None/mild | 59 (64.8) | 26 (52.0) | 33 (50.8) | |
Moderate/severe | 32 (35.2) | 13 (26.0) | 19 (29.2) | |
Treatment | 0.1494 | |||
Surgery only | 33 (29.7) | 11 (22.0) | 22 (33.9) | |
Postoperative or definitive | 78 (70.3) | 38 (76.0) | 40 (61.5) | |
Pathology histology | 0.8262 | |||
Well/moderately differentiated | 88 (76.5) | 39 (78.0) | 49 (75.4) | |
Poorly differentiated | 27 (23.5) | 11 (22.0) | 16 (24.6) | |
N-stage | 0.5492 | |||
N0/N1 | 75 (66.4) | 35 (70.0) | 40 (61.5) | |
N2 | 38 (33.6) | 15 (30.0) | 23 (35.4) | |
N-stage | 0.7055 | |||
N0 | 55 (48.7) | 23 (46.0) | 32 (50.8) | |
N1/N2 | 58 (51.3) | 27 (54.0) | 31 (49.2) | |
T-stage | 0.3433 | |||
T1/T2 | 64 (57.1) | 26 (52.0) | 38 (58.5) | |
T3/T4 | 48 (42.9) | 24 (48.0) | 24 (36.9) | |
Margin | 0.4762 | |||
Negative | 91 (80.5) | 37 (74.0) | 54 (83.1) | |
Positive | 22 (19.5) | 11 (22.0) | 11 (16.9) | |
Chemotherapy | 0.2321 | |||
No | 78(67.0) | 34 (68.0) | 44 (67.7) | |
Yes | 22 (33.0) | 13 (26.0) | 9 (13.9) | |
Patient status | 0.2577 | |||
Alive | 69 (60.0) | 27 (54.0) | 42 (64.6) | |
Dead | 46 (40.0) | 23 (46.0) | 23 (35.4) | |
Disease recurrence | 0.1330 | |||
No | 85 (73.9) | 33 (66.0) | 52 (80.0) | |
Yes | 30 (26.1) | 17 (34.0) | 52 (80.0) |
Value in bold is statistically significantly different between the Modeling and Test sets, P < 0.05.